glp-1 prader willi Frontiers | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in syndrome Current potential approaches for managing
Description
The FDA Wegovy label lists hair loss as an adverse reaction in 3% of adults and 4% of adolescents with obesity in clinical trials
Your labs look great, your A1C is perfect that's what matters
found that GLP-1 RAs are associated with an increased risk of gallbladder and biliary diseases (including cholelithiasis and cholecystitis), particularly at higher doses, longer treatment durations, and when used for weight loss [129]
By doing this, it helps reduce things like food noise that can encourage unhealthy eating habits
Tirzepatide is highly effective for weight loss
ElSayed NA, Aleppo G, Aroda VR et al (2023) 10
